Cargando…

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment

Major depressive disorder (MDD) is a common and disabling syndrome with multiple etiologies that is defined by clinically elicited signs and symptoms. In hopes of developing a list of candidate biological measures that reflect and relate closely to the severity of depressive symptoms, so-called “sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharyya, Sudeepa, Dunlop, Boadie W., Mahmoudiandehkordi, Siamak, Ahmed, Ahmed T., Louie, Gregory, Frye, Mark A., Weinshilboum, Richard M., Krishnan, Ranga R., Rush, A. John, Mayberg, Helen S., Craighead, W. Edward, Kaddurah-Daouk, Rima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751322/ https://www.ncbi.nlm.nih.gov/pubmed/31572108 http://dx.doi.org/10.3389/fnins.2019.00926

Ejemplares similares

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety—A Role for Bile Acids
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2022)

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
por: Brydges, Christopher R., et al.
Publicado: (2021)

The Metabolome-Wide Signature of Major Depressive Disorder
por: Jansen, Rick, et al.
Publicado: (2023)

Neuroimaging-based biomarkers for treatment selection in major depressive disorder
por: Dunlop, Boadie W., et al.
Publicado: (2014)

ERICH3: vesicular association and antidepressant treatment response
por: Liu, Duan, et al.
Publicado: (2020)

Neuroimaging Advances for Depression
por: Dunlop, Boadie W., et al.
Publicado: (2017)

Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
por: Joyce, Jeremiah B., et al.
Publicado: (2021)

Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
por: Tai, Hua-Hsin, et al.
Publicado: (2021)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway
por: Zhu, Hongjie, et al.
Publicado: (2013)

Metabolic Profiling of Patients with Schizophrenia
por: Kaddurah-Daouk, Rima
Publicado: (2006)

Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression
por: Nho, Kwangsik, et al.
Publicado: (2021)

Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts
por: St. John-Williams, Lisa, et al.
Publicado: (2019)

Peripheral serum metabolomic profiles inform central cognitive impairment
por: Wang, Jingye, et al.
Publicado: (2020)

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics
por: Liu, Duan, et al.
Publicado: (2018)

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer’s Disease
por: Baloni, Priyanka, et al.
Publicado: (2020)

Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder
por: Dunlop, Boadie W., et al.
Publicado: (2018)

Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism
por: Borkowski, Kamil, et al.
Publicado: (2023)

Targeted metabolomics and medication classification data from participants in the ADNI1 cohort
por: St John-Williams, Lisa, et al.
Publicado: (2017)

Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers
por: Nho, Kwangsik, et al.
Publicado: (2019)

Serum metabolomic biomarkers of perceptual speed in cognitively normal and mildly impaired subjects with fasting state stratification
por: Borkowski, Kamil, et al.
Publicado: (2021)

Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
por: Beger, Richard D., et al.
Publicado: (2020)

MiMeDB: the Human Microbial Metabolome Database
por: Wishart, David S, et al.
Publicado: (2022)

Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
por: Kaddurah-Daouk, Rima, et al.
Publicado: (2012)

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants
por: Rotroff, D M, et al.
Publicado: (2016)

Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer’s disease and progressive supranuclear palsy
por: Batra, Richa, et al.
Publicado: (2023)

Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
por: Arnold, Matthias, et al.
Publicado: (2020)

Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
por: Dunlop, Boadie W.
Publicado: (2020)

Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment
por: Trupp, Miles, et al.
Publicado: (2012)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics
por: Han, Xianlin, et al.
Publicado: (2011)

Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data
por: Jo, Taeho, et al.
Publicado: (2023)

Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder
por: Engelmann, Jan B., et al.
Publicado: (2013)

The United States index of socioeconomic deprivation for individuals (USiDep)
por: Dunlop, Boadie W., et al.
Publicado: (2022)

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
por: Kaddurah-Daouk, R, et al.
Publicado: (2011)

t(4) Workshop Report(): Quality Assurance of Metabolomics
por: Bouhifd, Mounir, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gmk5epl30642d4v9mr2qu2ria2